… clopidogrel for patients with acute coronary syndrome (ACS) based on randomized clinical
trial data in which ticagrelor reduced major adverse coronary events (MACE) vs clopidogrel …

… for patients with acute coronary syndrome (ACS), primarily based on a single large
randomized clinical trial. The benefits and risks associated with ticagrelor vs clopidogrel in routine …

… clopidogRel in non–ST- segment Elevation myocardial infarction), PLATO (Ticagrelor vs…
clopidogrel in patients with acute coronary syndromes) and PHILO (Ticagrelor vs. clopidogrel in …

… In STEMI, prasugrel is superior to clopidogrel,18 while ticagrelor's benefit is not as pronounced.19
Diabetics appear to have better outcomes with prasugrel, an advantage not seen with …

… percutaneous coronary intervention (PCI). The past 30 years has seen the progress from early
trials of clopidogrel … to identify a relatively small cohort who would benefit, and (5) the cost …

… and either 90 mg ticagrelor twice daily or 75 mg clopidogrel daily maintenance therapy. …
the benefit of switching from aspirin plus a newer P2Y12 blocker to aspirin plus clopidogrel 1 …

… There was still conflict on the antithrombotic advantage of ticagrelor versus clopidogrel
among East Asian population with acute coronary syndrome (ACS). We considered that the …

… Whether this benefit … clopidogrel, with either a 300- or 600-mg loading dose for the prevention
of periprocedural complications in patients undergoing percutaneous coronary intervention…

Full article: Comparisons between ticagrelor and clopidogrel following percutaneous coronary
intervention in patients with acute coronary syndrome: a comprehensive meta-analysis …

Background and objectives We sought to determine the frequency of use and association
between prasugrel and outcomes in acute coronary syndrome patients undergoing …